• Explore /
  • Poster
  • / A phase Ib/II study of second-line therapy with panitumumab, irinotecan and everolimus (PIE) in metastatic colorectal cancer (mCRC) with KRAS wild type (WT): Biomarker substudy.

A phase Ib/II study of second-line therapy with panitumumab, irinotecan and everolimus (PIE) in metastatic colorectal cancer (mCRC) with KRAS wild type (WT): Biomarker substudy.

Abstract Poster

Authors

null

Amanda Rose Townsend

The Queen Elizabeth Hospital, University of Adelaide, Adelaide, Australia

Amanda Rose Townsend , Jennifer Hardingham , Niall C. Tebbutt , Christos Stelios Karapetis , Nimit Singhal , Rohit Joshi , Sue Yeend , Pamela Cooper , Hilary Dorward , Timothy Jay Price

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2017 Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session C: Cancers of the Colon, Rectum, and Anus

Track

Cancers of the Colon, Rectum, and Anus

Sub Track

Translational Research

Clinical Trial Registration Number

NCT01139138

Citation

J Clin Oncol 35, 2017 (suppl 4S; abstract 643)

DOI

10.1200/JCO.2017.35.4_suppl.643

Abstract #

643

Poster Bd #

F17

Abstract Disclosures

Similar Posters

First Author: A. R. Townsend

First Author: Kohei Shitara

First Author: Cathy Eng

First Author: Marc Peeters